Company intelligence / Profile preview

Nirmayee

Ahmedabad, Gujarat, Indiafacebook.com ↗

Ownership: Private
Development stage: Commercial

Overview

Nirma is a large Indian conglomerate with significant operations in consumer goods and chemicals. Through its healthcare brand 'Nirlife', it is one of Asia's largest manufacturers of IV parenterals. In 2023-2024, it acquired Glenmark Life Sciences—an API manufacturer with a portfolio covering chronic therapeutic areas—for $681 million.

Therapeutic areas: OtherCardiovascularEndocrinologyNeurology
Modalities: Small moleculeInjectable drugs
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Nirmayee.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nirmayee.

Explore the full profile